Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality

Molecular Immunology

Volumn 44, Issue 7, 2007, Pages 1524-1534

  Scallon, Bernard J ^a   Tam, Susan H ^a   McCarthy, Stephen G ^a   Cai, Ann N ^a   Raju, T Shantha ^a  

^a CENTOCOR INC   (United States)

Author keywords

Antibodies; Antibody dependent cellular cytotoxicity; Fc receptors; Glycosylation; Sialic acid

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; SIALIC ACID;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; NATURAL KILLER T CELL; PRIORITY JOURNAL; PROTEIN STRUCTURE; SIALYLATION;

ANTIBODIES, MONOCLONAL; ANTIGENS; CARBOHYDRATE SEQUENCE; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MOLECULAR SEQUENCE DATA; N-ACETYLNEURAMINIC ACID; POLYSACCHARIDES; PROTEIN ENGINEERING; RECEPTORS, IGG;

EID: 33751253486     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.09.005     Document Type: Article

References (36)

1. Anumula K.R. Rapid quantitative determination of sialic acids in glycoproteins by high-performance liquid chromatography with a sensitive fluorescence detection. Anal. Biochem. 230 (1995) 24-30
2. Blomberg K., Hautala R., Lovgren J., Mukkala V.-M., Lindqvist C., and Akerman L. Time-resolved fluorometric assay for natural killer activity using target cells labeled with a fluorescence enhancing ligand. J. Immunol. Meth. 193 (1996) 199-206
3. Boyd P.N., Lines A.C., and Patel A.K. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol. Immunol. 32 (1995) 1311-1318
4. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., and Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99 (2002) 754-758
5. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry 20 (1981) 2361-2370
6. Dijstelbloem H.M., van de Winkel J.G.J., and Kallenberg C.G.M. Inflammation in autoimmunity: receptors for IgG revisted. Trends Immunol. 22 (2001) 510-516
7. Ferrara C., Stuart F., Sondermann P., Brünker P., and Umaña P. The carbohydrate at FcγRIIIa Asn-162: an element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281 (2006) 5032-5036
8. Fleit H.B., Wright S.D., and Unkeless J.C. Human neutrophil Fc gamma receptor distribution and structure. Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 3275-3279
9. Hodoniczky J., Zheng Y.Z., and James D.C. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 21 (2005) 1644-1652
10. Huber R., Deisenhofer J., Colman P.M., Matsushima M., and Palm W. Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature 264 (1976) 415-420
11. Jassal R., Jenkins N., Charlwood J., Camilleri P., Jefferis R., and Lund J. Sialylation of human IgG-Fc carbohydrate by transfected rat α2,6-sialyltransferase. Biochem. Biophys. Res. Commun. 286 (2001) 243-249
12. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 21 (2005) 11-16
13. Kaneko Y., Nimmerjahn F., and Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670-673
14. Knight D.M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., Scallon B., Moore M.A., Vilcek J., Daddona P., and Ghrayeb J. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30 (1993) 1443-1453
15. Krapp S., Mimura Y., Jefferis R., Huber R., and Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325 (2003) 979-989
16. Kumpel B.M., Rademacher T.W., Rook G.A.W., Williams P.J., and Wilson I.B.H. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum. Antibod. Hybrid. 5 (1994) 143-151
17. Leatherbarrow R.J., Rademacher T.W., Dwek R.A., Woof J.M., Clark A., Burton D.R., Richardson R., and Feinstein A. Effector functions of monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human Fc receptor. Mol. Immunol. 22 (1985) 407-415
18. Lund J., Takahashi N., Pound J.D., Goodall M., and Jefferis R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fcγ receptor I and influence the synthesis of its oligosaccharide chains. J. Immunol. 157 (1996) 4963-4969
19. Mimura Y., Church S., Ghirlando R., Ashton P.R., Dong S., Goodall M., Lund J., and Jefferis R. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol. Immunol. 37 (2000) 697-706
20. Nose M., and Wigzell H. Biological significance of carbohydrate chains on monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 6632-6636
21. Papac D.I., Wong A., and Jones A.J. Analysis of acidic oligosaccharides and glycopeptides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Chem. 68 (1996) 3215-3223
22. Papac D.I., Briggs J.B., Chin E.T., and Jones A.J. A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis. Glycobiology 8 (1998) 445-454
23. Raju T.S. Glycosylation variations with expression systems. BioProcess Int. 1 (2003) 44-53
24. Raju T.S., Briggs J.B., Chamow S.M., Winkler M.E., and Jones A.J.S. Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. Biochemistry 40 (2001) 8868-8876
25. Raju T.S., Briggs J.B., Borge S.M., and Jones A.J. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10 (2000) 477-486
26. Raju T.S., and Davidson E.A. Role of sialic acid on the viscosity of canine tracheal mucin glycoprotein. Biochem. Biophys. Res. Commun. 205 (1994) 402-409
27. Raju T.S., and Scallon B.J. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem. Biophys. Res. Commun. 341 (2006) 797-803
28. In: Robinson J.P., Darzynkiewiez A., Dean P.H., et al. (Eds). Current Protocols in Cytometry vol. 1 (2001), John Wiley & Sons, New York p. 5.1.3
29. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H.A., and Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2003) 26733-26740
30. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., Hanai N., and Shitara K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278 (2003) 3466-3473
31. Sondermann P., Kaiser J., and Jacob U. Molecular basis of immune complex recognition: a comparison of Fc-receptor structures. J. Mol. Biol. 309 (2001) 737-749
32. Tao M.-H., and Morrison S.L. Studies of aglycosylated chimeric mouse-human IgG: role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143 (1989) 2595-2601
33. Umaña P., Jean-Mairet J., Moudry R., Amstutz H., and Bailey J. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotech. 17 (1999) 176-180
34. Varki A., and Diaz S. The release and purification of sialic acids from glycoconjugates: methods to minimize the loss and migration of O-acetyl groups. Anal. Biochem. 137 (1984) 236-247
35. Wright A., and Morrison S.L. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J. Immunol. 160 (1998) 3393-3402
36. Yamane-Ohnuki N., Kinoshita S., Inoue-Urakubo M., Kusunoki M., Iida S., Nakano R., Wakitani M., Niwa R., Sakurada M., Uchida K., Shitara K., and Satoh M. Establishment of FUT8 knockout Chinese Hamster Ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotech. Bioeng. 87 (2004) 614-622